Aggressive Cancer Treatment: Multimodal Strategies and Emerging Advances

"Aggressive cancer" refers to high-grade, rapidly proliferative, or metastatic malignancies (e.g., triple-negative breast, pancreatic, glioblastoma, small cell lung cancer, advanced melanoma). While "cure" may not be achievable in advanced stages, modern multimodal therapy significantly extends survival and improves quality of life.

Treatment Modalities

• Surgery: Resection of primary ± oligometastases; cytoreduction.
• Systemic therapy: Chemotherapy (cytotoxic), targeted therapy (TKIs, mAbs, ADCs), immunotherapy (ICIs, CAR-T, bispecifics), endocrine therapy, radiopharmaceuticals.
• Radiation: Definitive, adjuvant, palliative, stereotactic (SRS/SBRT) for oligoprogression.
• Locoregional: HIPEC, TACE, TARE, ablation, isolated limb perfusion.

Personalization Drivers

• Molecular profiling (NGS, IHC, FISH) → actionable targets (EGFR, ALK, BRAF, HER2, NTRK, MSI-H, TMB).
• Germline testing (BRCA, Lynch) → PARP inhibitors, immunotherapy eligibility.
• Liquid biopsy (ctDNA) for monitoring, resistance detection.

Supportive and Palliative Care

Integrated early: symptom management (pain, nausea, dyspnea), psychosocial support, advance care planning, hospice when appropriate. Improves both quality and quantity of life.

Clinical Trials

Essential for accessing novel agents (bispecifics, KRAS inhibitors, novel ADCs, cell therapies). Discuss trial eligibility at each decision point.

A multidisciplinary tumor board ensures comprehensive, individualized strategy.